Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Jasper Therapeutics Q2 EPS $(0.29)

Jasper Therapeutics Q2 EPS $(0.29)

Jasper Therapeutics (NASDAQ:JSPR) reported quarterly losses of $(0.29) per share.

byMichael Horton

August 12, 2022

1 minute read

Jasper Therapeutics (NASDAQ:JSPR) reported quarterly losses of $(0.29) per share.

Goldman Sachs Initiates Coverage On Revance Therapeutics with Buy Rating, Announces Price Target of $33

By Benzinga Newsdesk

September 22, 6:20 AM

Goldman Sachs analyst Chris Shibutani initiates coverage on Revance Therapeutics (NASDAQ:RVNC) with a Buy rating and announces Price Target of $33.

RVNC

Morgan Stanley Downgrades Clarivate to Equal-Weight, Raises Price Target to $12

By Benzinga Newsdesk

February 6, 6:48 AM

Morgan Stanley analyst Toni Kaplan downgrades Clarivate (NYSE:CLVT) from Overweight to Equal-Weight and raises the price target from $11 to $12.

CLVT

News

AeroVironment Introduces Puma VNS, A Visual-Based Navigation System That Enables GPS-Denied Navigation Across GPS-Contested Environments

By Benzinga Newsdesk

September 15, 9:10 AM

System determines precise location of the aircraft during flight without relying on GPS Will enable increasingly advanced navigational capabilities, features and functionality through future software and hardware

AVAV

A Look Into Starbucks’ Debt

By Benzinga Insights

December 5, 10:17 AM

Shares of Starbucks Inc. (NASDAQ:SBUX) rose by 15.78% in the past three months. Before having a look at the importance of debt, let's look at how much debt Starbucks has.

SBUX

Jasper Therapeutics Q2 EPS $(0.29)

Related Posts

Goldman Sachs Initiates Coverage On Revance Therapeutics with Buy Rating, Announces Price Target of $33

Morgan Stanley Downgrades Clarivate to Equal-Weight, Raises Price Target to $12

AeroVironment Introduces Puma VNS, A Visual-Based Navigation System That Enables GPS-Denied Navigation Across GPS-Contested Environments

A Look Into Starbucks’ Debt